2024-12-25 - Analysis Report
## Johnson & Johnson (JNJ) Stock Report

**1. Performance Comparison & Divergence:**

Johnson & Johnson (JNJ), a diversified healthcare company, has significantly underperformed the S&P 500 (VOO) over the measured period.  While JNJ showed a cumulative return of 24.19%, VOO achieved a return of 117.56%. This represents a large divergence of -93.4%, placing it at the 4.6th percentile of its historical range of divergence against the S&P 500.  The provided alpha consistently shows negative values, indicating underperformance relative to the market benchmark.

**2. Recent Price Movement:**

* **Closing Price:** $145.27
* **Last Market Price:** $145.85
* **5-Day Moving Average:** $144.90
* **20-Day Moving Average:** $149.13
* **60-Day Moving Average:** $155.05

The current price is below all three moving averages, suggesting a downward trend.  The relatively small gap between the last market price and closing price indicates a stable day.


**3. Technical Indicators and Expected Return:**

* **RSI (29.06):**  Suggests the stock is currently in oversold territory.
* **PPO (-0.15):** Indicates bearish momentum.
* **20-Day Relative Divergence:** +4.6 suggests a recent short-term upward movement.
* **Expected Return (0.0%):**  The model predicts no significant excess return over the S&P 500 for long-term (2+ years) investment at this time.  The low expected return warrants caution.  A significant change from Last-Market to Closing prices would signal a dramatic increase or decrease and would change this analysis significantly.

**4. Recent Earnings Analysis:**

The recent earnings show a mixed picture. Revenue has remained relatively flat in the range of $21.35B to $22.47B for the last five quarters, indicating slow growth. EPS, however, is highly volatile with a significant drop in the last reported quarter (2024-10-23) to $1.12.  The previous quarter EPS of $1.95 was higher, which was also preceded by a period of above $1.00 EPS.  There's no information available here to compare to analyst expectations.  Further analysis is needed to determine reasons for such variability in EPS.


**5. Financial Information Analysis:**

* **Revenue:**  Revenue has remained relatively stable over the past year, with slight fluctuations.
* **Profit Margin:** Profit margins are consistently high, ranging from 68.23% to 69.55%, suggesting strong profitability.
* **Equity & ROE:** Equity levels fluctuate slightly quarter to quarter.  The Return on Equity (ROE) shows significant variability, notably a very high ROE of 36.54% in 2023-09-30 compared to the significantly lower values in other recent quarters, indicating substantial change in the underlying metrics which could use further analysis.

**6. News and Recent Issues:**

This section requires external data.  To complete this section, information needs to be gathered on news, market outlook, and analyst opinions from credible financial news sources within the last two days, specifically concerning JNJ's earnings announcements and market performance.

**7.  Overall Analysis:**

JNJ's performance significantly lags behind the S&P 500. While it shows strong profit margins, recent EPS volatility and a downward price trend raise concerns.  Oversold conditions (RSI) suggest a potential short-term bounce, but the negative PPO and low expected return indicate limited upside potential in the long term relative to the market. Further investigation into the factors driving the highly variable ROE and EPS are crucial before any investment decision.  News and analyst opinions, specifically concerning the most recent earnings report, are essential to a more complete assessment.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investment decisions should be made based on thorough research and consideration of individual risk tolerance. The analysis is limited by the data provided and may not reflect the complete picture.
